Literature DB >> 2419672

Cardiovascular effects of ketanserin in the treatment of hypertension during coronary artery bypass surgery.

J A Richter, A Barankay, E Göb, P Späth.   

Abstract

The cardiovascular effects of ketanserin (5-HT2-receptor antagonist with alpha 1-receptor blocking property) were studied during coronary artery surgery. Sixteen patients were anesthetized with flunitrazepamfentanyl-nitrous oxide-oxygen-pancuronium. Ketanserin (10 mg i.v.) was used to decrease elevated blood pressure unresponsive to deepening of anesthesia before extracorporeal circulation. Ketanserin caused a marked vasodilation in all patients, significant (p less than 0.05) decreases of systolic, diastolic, and mean arterial blood pressure, and of pulmonary artery pressure and pulmonary capillary wedge pressure. As a result, indirect indices of myocardial oxygen demand (rate-pressure product and "triple index") also decreased. Heart rate and right atrial pressure remained unchanged, while cardiac index and stroke volume index increased slightly. Ketanserin was found to be effective in the treatment of prebypass hypertension; the elevated blood pressure returned to normal; unwanted hypotension was not observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419672     DOI: 10.1097/00005344-198601000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  5-Hydroxytryptamine induces contraction in isolated human mammary artery: effect of ketanserin.

Authors:  A Monopoli; A Conti; A Forlani; E Ongini; C Antona; P Biglioli
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

3.  Pharmacological actions of the selective and non-selective beta-adrenoceptor antagonists celiprolol, bisoprolol and propranolol on human bronchi.

Authors:  R W Hauck; C Schulz; H P Emslander; M Böhm
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.